Citigroup’s Revance Therapeutics, Inc. RVNC Stock Holding History

Citigroup’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-227,100	Closed	-$2M	–	5887
2023 Q4	$2M	Buy	227,100 +42,300	+23%	+$347K	﹤0.01%	2239
2023 Q3	$2.12M	Buy	184,800 +24,900	+16%	+$479K	﹤0.01%	1939
2023 Q2	$4.05M	Sell	159,900 -69,700	-30%	-$2.17M	﹤0.01%	1635
2023 Q1	$7.4M	Sell	229,600 -70,400	-23%	-$2.19M	0.01%	1296
2022 Q4	$5.54M	Sell	300,000 -1,516,600	-83%	-$34.7M	﹤0.01%	1423
2022 Q3	$49M	Buy	1,816,600 +1,751,800	+2,703%	+$35.5M	0.04%	383
2022 Q2	$896K	Buy	+64,800	New	+$998K	﹤0.01%	2750

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's RVNC Position: Q1 2025 in Review

Citigroup sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 90,172 shares — an estimated $274K sold.

Citigroup first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $1.92M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Citigroup reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Citigroup sold 90,172 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $274K.
Citigroup first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
Citigroup's Revance Therapeutics, Inc. position peaked at $1.92M in Q3 2022.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.